Temporary mechanical circulatory support (heart pumps)

Temporary mechanical circulatory support means a pump or similar device that helps the heart pump blood for a limited time. A 2026 review of randomized trials in adults with cardiogenic shock after a heart attack looked at three kinds: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. The review says no device gives universal benefit in this varied group. Routine Impella CP support lowered 180-day mortality in carefully selected patients in one trial, with more major bleeding and other complications.

Also called MCS

  • Technology
  • In this atlas

Overview

Technical summary

MeSH descriptor D006353 (Heart-Assist Devices) is recorded as a broad match: its scope note describes small pumps, often implantable, designed for temporarily assisting the heart, usually the left ventricle, to pump blood. FDA product code OZD (Temporary Non-Roller Type Left Heart Support Blood Pump) is also broad, and it covers left-heart pumps only. The US approval facts are for one device family, the Impella left-heart pumps (premarket approval P140003). The trial evidence comes from the abstract of one 2026 review, not from the trial reports.

How it works

Temporary circulatory support devices assist the heart's pumping for a limited time. In the United States the Impella left-heart pumps hold premarket approval P140003. Its approval orders state an indication for high-risk percutaneous coronary intervention (2015), one for ongoing cardiogenic shock within 48 hours after a heart attack or open heart surgery (2016), and one that also covers cardiogenic shock in the setting of cardiomyopathy or myocarditis (2018). The shock indications apply to isolated left ventricular failure that does not respond to optimal medical management.

Classification codes

  • MeSH MeSH linked-data concept M0009976 of descriptor D006353 (Heart-Assist Devices) fetched on 2026-10-30; the descriptor is wider than temporary support D006353
  • FDA product code openFDA device classification endpoint, retrieved 2026-10-30 OZD Temporary Non-Roller Type Left Heart Support Blood Pump

Strengths

  • In the DanGer Shock trial, as summarized in a 2026 review, routine Impella CP support reduced 180-day mortality in carefully selected patients with cardiogenic shock after a ST-elevation heart attack.

Limitations

  • The same review says no temporary support device provides universal benefit across the varied group of adults with cardiogenic shock after a heart attack.
  • In DanGer Shock the benefit came with more major bleeding, limb ischemia, acute kidney injury and renal replacement therapy.
  • Routine balloon pump use has not been linked to better survival, and other trials did not show a survival benefit from routine early venoarterial extracorporeal membrane oxygenation in broad populations, with more bleeding and vascular complications.
  • The evidence recorded here is the review's abstract; the US approval records read cover one device family (product code OZD).

Required infrastructure

  • The review says Impella CP should be used selectively in patients with mainly left ventricular failure treated within experienced shock systems.

Claims and evidence

Context Adults with cardiogenic shock after an acute heart attack, as covered by a 2026 review of randomized trials of temporary mechanical circulatory support

Recipient
Adult
Population
Adult patients with acute myocardial infarction-related cardiogenic shock (AMI-CS), as the abstract states the review population. The review looked at randomized trials and analyses of them from January 2021 through June 2026.
Care setting
Hospital intensive care and shock systems of care; the abstract mentions experienced shock systems
Geography
Not stated in the abstract
Life stage
Adults
Follow-up
Not applicable (review). The abstract names 180-day mortality for one trial and gives no other follow-up.
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adults with acute myocardial infarction-related cardiogenic shock
Excluded
None stated
  • Description Evidence synthesis Certainty not assessed

    The abstract of a 2026 open-access review of randomized trials in adults with cardiogenic shock after an acute heart attack covers three kinds of temporary support: the intra-aortic balloon pump, microaxial flow pumps and venoarterial extracorporeal membrane oxygenation. It says recent randomized evidence shows that no temporary support device gives universal benefit across this varied group. It says routine balloon pump use has not been linked to better survival. It says the DanGer Shock trial showed lower 180-day mortality with routine Impella CP support in carefully selected patients with STEMI-related cardiogenic shock, with more major bleeding, limb ischemia, acute kidney injury and renal replacement therapy. It says other trials did not show a survival benefit from routine early venoarterial extracorporeal membrane oxygenation in broad populations. The review concludes that the role of temporary support has moved from routine device use toward individualized, phenotype-guided therapy, and that Impella CP should be used selectively in patients with mainly left ventricular failure treated within experienced shock systems.

    Applies to Adult Adults with cardiogenic shock after an acute heart attack, as covered by a 2026 review of randomized trials of temporary mechanical circulatory support

    Certainty method
    Not assessed
    Limitations
    Only the abstract of the review was read. The trial reports, the numbers of deaths and the review's search and selection methods beyond the abstract were not read, so the atlas records no effect size. The statements on DanGer Shock and the other trials are the review's, not read from the trial reports. A review summarizes trials and is not a trial. The review limits itself to heart-attack-related cardiogenic shock in adults and does not cover cardiogenic shock from other causes.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (12)
    1. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 1
      How it applies
      Background of the review.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    2. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 3
      How it applies
      Population of the review.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    3. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 4, fragment 1 of 2
      How it applies
      Kinds of support covered.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    4. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 4, fragment 2 of 2
      How it applies
      Kinds of support covered.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    5. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 6
      How it applies
      Main result.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    6. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 7, fragment 1 of 2
      How it applies
      Balloon pump.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    7. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 8, fragment 2 of 2
      How it applies
      DanGer Shock result.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    8. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 9
      How it applies
      Harms that came with the benefit.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    9. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 11, fragment 1 of 2
      How it applies
      Extracorporeal membrane oxygenation trials.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    10. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 13
      How it applies
      Conclusion.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    11. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 14, fragment 1 of 2
      How it applies
      Selective use of Impella CP.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.
    12. Supports Temporary Mechanical Circulatory Support in Acute Myocardial Infarction-Related Cardiogenic Shock: Lessons from Contemporary Randomized Trials

      Publication · Journal of Clinical Medicine · Edition PMC Open Access subset full-text XML, from NCBI E-utilities, fetched 2026-10-30. Only the abstract was read for this atlas. · PMCID: PMC13665844 · PMID: 42882125 · DOI: 10.3390/jcm15197664

      Locator
      Abstract, sentence 14, fragment 2 of 2
      How it applies
      Selective use of Impella CP.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      ee6acdf16f240ed3649ed4f81c97616891fc428751c47d4aee5699bcf221580c
      Reuse basis
      PMC Open Access subset article under https://creativecommons.org/licenses/by/4.0/. The article's own permissions element states the licence. The XML is committed unaltered, with the citation and licence kept in the file. The raw file is committed in the atlas repository.

Context Patients described in the US premarket approval orders for the Impella heart pump (high-risk PCI, and cardiogenic shock after heart attack, heart surgery, cardiomyopathy or myocarditis)

Recipient
Recipient not specified
Population
The approval orders describe patients undergoing high-risk percutaneous coronary intervention with severe coronary artery disease and depressed left ventricular ejection fraction (2015), and patients with ongoing cardiogenic shock from isolated left ventricular failure after acute myocardial infarction or open heart surgery (2016), or in the setting of cardiomyopathy or myocarditis (2018).
Care setting
Not stated in the FDA records beyond a hospital procedure or intensive care implied by the indications
Geography
United States (decisions by the US Food and Drug Administration)
Life stage
Not stated in the FDA records
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    The openFDA record of premarket approval P140003, with Abiomed, Inc. as applicant, lists approval of the IMPELLA 2.5 System on 23 March 2015. The approval order describes a temporary ventricular support device used during high-risk percutaneous coronary intervention in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction. Supplement S004, approved on 7 April 2016, states an indication for ongoing cardiogenic shock that occurs within 48 hours after acute myocardial infarction or open heart surgery, as a result of isolated left ventricular failure that is not responsive to optimal medical management and conventional treatment measures. Supplement S018, approved on 7 February 2018, states an indication for ongoing cardiogenic shock that occurs immediately after those events or in the setting of cardiomyopathy, including peripartum cardiomyopathy, or myocarditis, again as a result of isolated left ventricular failure that is not responsive to optimal medical management.

    Applies to Recipient not specified Patients described in the US premarket approval orders for the Impella heart pump (high-risk PCI, and cardiogenic shock after heart attack, heart surgery, cardiomyopathy or myocarditis)

    Certainty method
    Not assessed
    Limitations
    This claim covers one device family, the Impella left-heart pumps approved under P140003 (product code OZD). It does not cover other temporary support, such as the intra-aortic balloon pump or venoarterial extracorporeal membrane oxygenation, or the Impella RP, which has its own approval. Only three of the many records for P140003 are read, and later supplements may change the wording. An FDA approval is a decision about a device, not a finding about how well it works. The approval orders are paraphrased from the openFDA statements, which openFDA says it does not validate and not to rely on for decisions about medical care.
    Last checked
    2026-10-30
    Next evidence check due
    Not scheduled
    Sources and citations (12)
    1. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].pma_number
      How it applies
      Approval number.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    2. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].applicant
      How it applies
      Applicant.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    3. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].trade_name
      How it applies
      Trade name of the original approval.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    4. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].decision_date
      How it applies
      Decision date of the original approval.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    5. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].decision_code
      How it applies
      Decision code (APPR).
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    6. Supports FDA premarket approval P140003: IMPELLA 2.5 System (openFDA records of the original approval and its first supplements)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The first three openFDA PMA records of P140003 by decision date, returned on 2026-10-30: the original approval (decision date 2015-03-23) and supplements S002 and S003. Dataset last updated 2026-10-19. · PMA: P140003

      Locator
      results[0].ao_statement
      How it applies
      Approval order statement of the original approval.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      7a68a9b089f93c68d73cdc38b5678d645da51e035d0dae4524d5d2241d105d44
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    7. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[0].supplement_number
      How it applies
      Supplement S004.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    8. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[0].decision_date
      How it applies
      Decision date of S004.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    9. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[0].ao_statement
      How it applies
      Approval order statement of S004.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    10. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[2].supplement_number
      How it applies
      Supplement S018.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    11. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[2].decision_date
      How it applies
      Decision date of S018.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.
    12. Supports FDA premarket approval P140003: supplements whose approval order mentions cardiogenic shock (openFDA records)

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The five openFDA PMA records of P140003 whose approval order statement contains the word cardiogenic, returned on 2026-10-30 in decision-date order: S004 (2016-04-07), S005 (2016-04-07), S018 (2018-02-07), S066 (2020-01-22) and S106 (2023-01-06). Dataset last updated 2026-10-19.

      Locator
      results[2].ao_statement
      How it applies
      Approval order statement of S018.
      Retrieved
      Source effective date
      2026-10-19
      Source state
      Current
      Version fingerprint
      03c3a2b7a7e294899c0d94a126a36180bf79a22b3fcebf3b914661c35fafd2dd
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-10-30, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2). The raw record is committed in the atlas repository. It includes contact, address and registration fields that FDA publishes; records here do not repeat them.

Record details

Record id
cardio:mechanical-circulatory-support
Content hash
9b6fb7ba7086d7c82aa083e9942136b551d13f2425e9ae00d5384de18f079b6f